Skip to content
DataLookout
Menu

NCT00996710

Genomic Structural Variation in Cancer Susceptibility

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 27 versions: 21 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2026 to Oct 2027
    • Eligibility criteria expanded, about 14 words
    • Primary endpoints: details revised at 1 of 1 entry
  2. Notable Primary and study completion dates: Oct 2025 to Oct 2026v26
  3. Notable Primary and study completion dates: Oct 2024 to Oct 2025v25
  4. Notable Primary and study completion dates: Oct 2023 to Oct 2024v24
  5. Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 1850 to confirmed 1275
    v23
Show 15 earlier versionsHide 15 earlier versions
  1. Notable Primary and study completion dates: Oct 2021 to Oct 2023v21
  2. Notable Primary and study completion dates: Oct 2020 to Oct 2021v20
  3. Notable Primary and study completion dates: Oct 2019 to Oct 2020v19
  4. Notable Primary and study completion dates: Oct 2018 to Oct 2019v17
  5. Minor Enrollment target: 1250 to 1850v15
  6. Notable Primary and study completion dates: Oct 2017 to Oct 2018v14
  7. Notable Eligibility criteria expanded, about 35 wordsv13
  8. Notable Primary and study completion dates: Oct 2016 to Oct 2017v12
  9. Notable Primary and study completion dates: Oct 2015 to Oct 2016v11
  10. Notable Primary and study completion dates: Oct 2014 to Oct 2015
    • Collaborators: 3 to 4
    v9
  11. Notable Eligibility criteria expanded, about 38 words
    • Secondary endpoints: details revised at 1 of 1 entry
    v8
  12. Notable Primary and study completion dates: Oct 2013 to Oct 2014v7
  13. Notable Primary and study completion dates: Oct 2011 to Oct 2013v5
  14. Notable Eligibility criteria expanded, about 12 wordsv4
  15. Notable Eligibility criteria revisedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To determine the frequency of de novo germline copy number variants (CNVs) in cancer affected probands using an ascertainment of "trios" consisting of cancer patients and their unaffected biologic parents
Timeframe: 2 years

Secondary (1)

To explore the role of germline homozygosity in cancer susceptibility by determining the frequency and length of autozygous regions in patients with cancer

Sites

1 site in 1 country

  • Memorial Sloan Kettering Cancer CenterNew York, New York, United States